Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

PRICED: Phoenix Pharma EUR400m 5NCL sr 2.375% at 99.419 yld 2.50%

HYC European Market: Deal Flow - General

PHOENIX PIB Dutch Finance BV (Phoenix Pharma) (PHARGR) EUR400m (up from EUR300m) Reg S sr notes due Aug 05, 2025 (5y). NCL (3mo par call, clean-up call). NR/BB+ (--/negative). Gtd by PHOENIX Pharmahandel GmbH & Co KG / PHOENIX International Beteiligungs GmbH. Via CA/Commerz/ING/UniCredit (B&D) joint books (ING coordinated logistics). List Lux. German law. Annual pay (Act/Act). 100x100. Settles 08/05 (T+5). ISIN: XS2212959352. Relevant stabilization regulations including FCA/ICMA will apply. Investor feedback was in the 2.50%-3.00% range. IPT: 2.75% area. Px talk: 2.50% area. Final terms: EUR400m 2.375% coupon to yield 2.50%.

Priced: 2.375% at 99.419, yield 2.50%. +321.2bp vs OBL 0% 04/11/25. MS+288bp.

Did investor call on 27 July at 10:30am UKT and a series of one-on-one and small group fixed income investor calls July 27-28. Books went subject at 12pm UKT today. Book size greater than EUR815m (pre rec) at IPT, greater than EUR740m (pre rec) at guidance. Final book around EUR690m. UOP: GCP including. refinancing of existing Phoenix Pharma Group debt. Biz: a leading integrated healthcare provider in Europe operating in Pharmaceutical Wholesale, Pharmaceutical Retail and Pharma Services. HQ: Mannheim, Germany.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.